Aquestive Therapeutics, Inc. (AQST)

Over the past six months, Aquestive Therapeutics' stock has been impacted by events related to Anaphylm, including a price target slash by Cantor due to FDA deficiencies, leading to a significant stock drop. In March 2026, Aquestive reported a Q4 2025 EPS miss and revenue below consensus. Despite these misses, the stock had seen a 3-month and 6-month increase of 37.20% as of April 12, 2026. Analyst consensus as of April 10, 2026, was a "Buy" rating, with an average 12-month target price of $8.80. Insider selling of 395,690 shares occurred in the last quarter.

While specific demand seasonality for Aquestive Therapeutics' products is not detailed, the healthcare sector generally has seasonal strength from April 25 to December 4. A seasonal analysis of AQST stock suggests a "Buy Date" of July 4 and a "Sell Date" of November 29, historically resulting in a geometric average return of 48.32% above the S&P 500 Total Return Index, but this is based on only seven years of data.

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative products, particularly in CNS conditions and severe allergies, leveraging its PharmFilm® technology. The company's business model involves internal product development, manufacturing, and licensing arrangements. Major commercialized products include Suboxone® Sublingual Film, Sympazan® Oral Film, Ondif® Oral Film, Azstarys®, Exservan™ Oral Film, and Emylif® Oral Film. The company's proprietary pipeline includes Libervant® Buccal Film, Anaphylm™ Sublingual Film, AQST-108, and AQST-305.

Aquestive Therapeutics is headquartered in Warren, New Jersey, with the majority of its revenue coming from the United States. The company also has commercialized products marketed internationally, including Ondif® in Brazil and Emylif® in Europe. Aquestive aims to expand its presence in international markets through strategic partnerships and licensing agreements.

Aquestive Therapeutics' brand reputation has been influenced by regulatory challenges and analyst reassessments, particularly the FDA's identification of deficiencies in the Anaphylm NDA, leading to a securities class action lawsuit. Despite these challenges, the company continues to receive an average "Buy" rating from brokerages.

Aquestive Therapeutics is owned by a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 59.15% of the stock, while insiders own about 6.65%, and retail investors hold 34.20%. Major institutional owners include Bratton Capital Management, L.P., BlackRock, Inc., and Vanguard Group Inc. Douglas K. Bratton is the largest individual shareholder, owning 1.61% of the company, and Daniel Barber, the CEO, holds 0.8% of the shares.